A5057308359- Extracellular vesicles in disease
- Prostate Cancer Treatment and Research
- MicroRNA in disease regulation
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Cell Adhesion Molecules Research
- Circular RNAs in diseases
- Genomics, phytochemicals, and oxidative stress
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Advanced Proteomics Techniques and Applications
- Sirtuins and Resveratrol in Medicine
- Ubiquitin and proteasome pathways
- Calcium signaling and nucleotide metabolism
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Autophagy in Disease and Therapy
- Bone health and treatments
- Nanoplatforms for cancer theranostics
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Advanced biosensing and bioanalysis techniques
- Bone and Joint Diseases
- Adenosine and Purinergic Signaling
- Epigenetics and DNA Methylation
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2013-2024
Cedars-Sinai Medical Center
2015-2016
// Valentina R. Minciacchi 1 , Sungyong You Cristiana Spinelli Samantha Morley 2 Mandana Zandian Paul-Joseph Aspuria 3 Lorenzo Cavallini 1,4 Chiara Ciardiello 1,5 Mariana Reis Sobreiro Matteo Morello Geetanjali Kharmate 6 Su Chul Jang 7 Dae-Kyum Kim Elham Hosseini-Beheshti Emma Tomlinson Guns Martin Gleave Yong Song Gho Suresh Mathivanan 8 Wei Yang Michael Freeman 1,2 and Dolores Di Vizio Division of Cancer Biology Therapeutics, Departments Surgery, Biomedical Sciences Pathology Laboratory...
Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed characterized DU145R80 subline, selected from parental DU145 cells resistant inhibitors mevalonate pathway. showed different proteomic profile compared cells, along with altered cytoskeleton dynamics a more...
Abstract Background Triple negative breast cancer (TNBC) is an aggressive disease characterized by high risk of relapse and development resistance to different chemotherapy agents. Several targeted therapies have been investigated in TNBC with modest results clinical trials. Among these, PI3K/AKT inhibitors evaluated addition standard therapies, yielding conflicting making attempts on elucidating inherent mechanisms great interest. Increasing evidences suggest that can induce autophagy...
Abstract Background Despite the introduction of several novel therapeutic approaches that improved survival, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Herein we report synergistic antitumor interaction between two well-known drugs used for years in clinical practice, antiepileptic agent with histone deacetylase inhibitory activity valproic acid and cholesterol lowering simvastatin, mCRPC models. Methods Synergistic anti-tumor effect was assessed on...
Patients with advanced prostate cancer (PCa) and multiple myeloma (MM) have limited long-term responses to available therapies. The histone deacetylase inhibitor panobinostat has shown significant preclinical clinical anticancer activity in both hematological solid malignancies is currently phase III trials for relapsed MM. Bisphosphonates (BPs), such as zoledronic acid (ZOL), inhibit osteoclast-mediated bone resorption are indicated the treatment of metastasis. BPs, including ZOL, also...
Abstract Despite progress in the prevention and diagnosis of cancer, current technologies for tumor detection present several limitations including invasiveness, toxicity, inaccuracy, lengthy testing duration high cost. Therefore, innovative diagnostic techniques that integrate knowledge from biology, oncology, medicinal analytical chemistry are now quickly emerging attempt to address these issues. Following this approach, here we developed a paper-based electrochemical device detecting...
Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with poor prognosis. The combination of cisplatin (CDDP) plus cetuximab (CX) one the standard first-line treatments in this disease. However, therapeutic regimen often associated high toxicity resistance, suggesting that new combinatorial strategies are needed to improve its index. In our study, we evaluated antitumor effects valproic acid (VPA), well-known antiepileptic agent histone...
Proteomic analysis identified differentially expressed proteins between zoledronic acid-resistant and aggressive DU145R80 prostate cancer (PCa) cells their parental DU145 cells. Ingenuity Pathway Analysis (IPA) showed a strong relationship the within network associated with homogeneous cellular functions prevalently related regulation of cell organization, movement consistent smaller reduced cell-cell contact morphology The correlated in publically available human PCa genomic data increased...
ErbB3, a member of the ErbB family receptors, has key role in development and progression several cancers, including non-small cell lung cancer (NSCLC), establishment resistance to therapies, leading anti-ErbB3 therapies.In this study we demonstrated, set malignant pleural effusion-derived cultures NSCLC, synergistic antitumor effect histone deacetylase inhibitor (HDACi), such as vorinostat or valproic acid (VPA), combination with monoclonal antibody (MoAb) A3. Synergistic interaction was...
Abstract Introduction: docetaxel (DTX) represents the standard of care first line treatment castration-resistant prostate cancer (PCa). However, onset systemic side effects hampers patient's compliance and DTX resistance invariably emerges, leading to disease relapse, suggesting need novel combination strategies. Cancer stem cells (CSC) drive PCa survival metastasis are thought be responsible for development DTX. The mevalonate pathway (MVP) plays a critical role in progression is implicated...
Abstract In the last years several evidences suggested that ErbB3, a member of HER family receptors, has key role in development and progression cancers including non-small cell lung cancer (NSCLC), above all establishment resistance to therapies, leading major efforts towards anti-ErbB3 therapies. We recently demonstrated head neck cells that, depending on ErbB3 expression level tumor phenotype (epithelial vs mesenchymal), vorinostat, one two clinically approved histone deacetylase...
Abstract Although docetaxel (DTX) remains a standard of care for advanced prostate cancer (PCa), limited long-term responses, side effects and resistant disease suggested the need novel combination strategies. Increased expression histone deacetylases (HDAC) alteration mevalonate pathway (MVP) are common aberrations in PCa. In this study, we analyzed antitumor effect DTX with valproic acid (VPA), an anticonvulsant HDAC inhibitory activity, simvastatin (SIM), cholesterol-lowering drug...
Abstract We have recently established a zoledronic acid-resistant prostate cancer cell line, DU145R80,which exhibits higher invasive capability compared to parental DU145 cells, and epithelial-to-mesenchymal transition (EMT)[Milone MR, Cell Death Dis. 2013]. To investigate the mechanism by which cells become invasive, we DU145R80 proteomic approach, unveiling signaling network that links interior of nucleus changes in cytoskeleton dynamics extracellular matrix, dictating aggressiveness...
Abstract INTRODUCTION: Recurrent metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) is a devastating malignancy with poor prognosis combination cisplatin (CDDP) plus cetuximab (CX) one gold standard for first-line treatment. However, this therapy often associated toxicity resistance, suggesting that new combinatorial strategies are needed to improve therapeutic index regimen. In our study, we evaluated synergistic antitumor effect valproic acid (VPA), an anticonvulsant...